drugset / Trial / NCT05904379
AK112 and AK104 With or Without Chemotherapy in Advanced Non-small Cell Lung Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
This trial is a Phase Ib/II study. All patients are stage IIIB/C (unsuitable for radical therapy) or IV non-small cell lung cancer(NSCLC), Eastern Cooperative Oncology Group (ECOG) performance status 0-1. The purpose of this study is to evaluate the safety and efficacy of AK112 and AK104 with or without chemotherapy in subjects with advanced NSCLC.
Timeline
- Start
- 2023-07-13
- Primary completion
- 2026-06-30
- Completion
- 2027-01-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cadonilimab | Monoclonal antibody | — | Intravenous |
| Subject | Carboplatin | Small molecule | — | Intravenous |
| Subject | Docetaxel | Small molecule | — | Intravenous |
| Subject | Ivonescimab | Monoclonal antibody | — | Intravenous |
| Subject | Paclitaxel | Small molecule | — | Intravenous |
| Subject | Pemetrexed | Small molecule | — | Intravenous |